Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
COLL
Upturn stock ratingUpturn stock rating

Collegium Pharmaceutical Inc (COLL)

Upturn stock ratingUpturn stock rating
$29.71
Last Close (24-hour delay)
Profit since last BUY1.26%
upturn advisory
Consider higher Upturn Star rating
BUY since 22 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/16/2025: COLL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $41.25

1 Year Target Price $41.25

Analysts Price Target For last 52 week
$41.25Target price
Low$23.23
Current$29.71
high$42.29

Analysis of Past Performance

Type Stock
Historic Profit 17.23%
Avg. Invested days 37
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/16/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 962.02M USD
Price to earnings Ratio 24.53
1Y Target Price 41.25
Price to earnings Ratio 24.53
1Y Target Price 41.25
Volume (30-day avg) 5
Beta 0.65
52 Weeks Range 23.23 - 42.29
Updated Date 06/30/2025
52 Weeks Range 23.23 - 42.29
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 1.22

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 6.61%
Operating Margin (TTM) 13.71%

Management Effectiveness

Return on Assets (TTM) 7.95%
Return on Equity (TTM) 19.23%

Valuation

Trailing PE 24.53
Forward PE 4.37
Enterprise Value 1608133384
Price to Sales(TTM) 1.45
Enterprise Value 1608133384
Price to Sales(TTM) 1.45
Enterprise Value to Revenue 2.42
Enterprise Value to EBITDA 4.83
Shares Outstanding 32142200
Shares Floating 27235365
Shares Outstanding 32142200
Shares Floating 27235365
Percent Insiders 1.69
Percent Institutions 117.12

Analyst Ratings

Rating 3
Target Price 41.25
Buy 2
Strong Buy 2
Buy 2
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Collegium Pharmaceutical Inc

stock logo

Company Overview

overview logo History and Background

Collegium Pharmaceutical, Inc. was founded in 2003. Initially focused on developing abuse-deterrent opioid products, it has evolved through acquisitions and pipeline development.

business area logo Core Business Areas

  • Pain Management: Develops and commercializes products for the treatment of pain, with a focus on abuse-deterrent formulations and non-opioid pain relievers.
  • Specialty Pharmaceutical: Focuses on specialized pharmaceutical products targeting specific patient populations and therapeutic areas.

leadership logo Leadership and Structure

The company is led by a management team with experience in the pharmaceutical industry. The organizational structure consists of functional departments including R&D, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Xtampza ER: Xtampza ER (oxycodone extended-release) is an abuse-deterrent opioid analgesic. Competitors include other extended-release opioids from companies like Purdue Pharma (bankruptcy), Teva Pharmaceuticals (TEVA), and Endo International (bankruptcy).
  • Nucynta ER: Nucynta ER (tapentadol extended-release) is indicated for the management of severe chronic pain in adults when continuous, around-the-clock opioid treatment is needed for an extended period of time. The competitors are other extended release opioids from companies like Purdue Pharma (bankruptcy), Teva Pharmaceuticals (TEVA), and Endo International (bankruptcy).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and competition from generic drugs. The pain management segment faces challenges related to the opioid crisis and increasing demand for non-opioid alternatives.

Positioning

Collegium Pharmaceutical Inc. is positioned as a specialty pharmaceutical company with a focus on abuse-deterrent pain medications. Its competitive advantages lie in its proprietary technologies and targeted marketing strategies.

Total Addressable Market (TAM)

The TAM for pain management medications is substantial. Collegium Pharmaceutical Inc. aims to capture a share of this market through its differentiated product offerings. The total pain management market is estimated to be tens of billions of dollars annually, however, Collegium Pharmaceutical's specific TAM within this is smaller, based on its areas of focus.

Upturn SWOT Analysis

Strengths

  • Abuse-deterrent technology
  • Focused product portfolio
  • Experienced management team

Weaknesses

  • Reliance on opioid market
  • Limited product pipeline diversity
  • Small market capitalization

Opportunities

  • Expansion into non-opioid pain treatments
  • Strategic partnerships and acquisitions
  • Geographic expansion

Threats

  • Increasing regulatory scrutiny of opioids
  • Competition from generic drugs
  • Opioid crisis and potential litigation

Competitors and Market Share

competitor logo Key Competitors

  • TEVA
  • ENDP

Competitive Landscape

Collegium Pharmaceutical Inc. faces competition from both branded and generic pharmaceutical companies. Its competitive advantage lies in its abuse-deterrent technology, but it needs to diversify its product portfolio.

Major Acquisitions

BioDelivery Sciences International, Inc.

  • Year: 2022
  • Acquisition Price (USD millions): 604
  • Strategic Rationale: To expand its pain portfolio and pipeline with non-opioid pain management products.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data not available without live data feeds. Requires API access.

Future Projections: Future growth projections data not available without live data feeds. Requires API access.

Recent Initiatives: Recent initiatives include product development efforts aimed at introducing new pain management solutions and expanding market presence.

Summary

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company focused on pain management, primarily known for abuse-deterrent opioid formulations. It is working to diversify its portfolio into non-opioid products. Regulatory scrutiny and litigation related to opioids pose challenges, but strategic acquisitions could support future growth. Diversification efforts are key to longer term success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Analyst Reports
  • Industry News

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Financial data requires live data feeds. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Collegium Pharmaceutical Inc

Exchange NASDAQ
Headquaters Stoughton, MA, United States
IPO Launch date 2015-05-07
CEO, President, Executive VP & Director Mr. Vikram Karnani
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 357
Full time employees 357

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.